(thirdQuint)The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial.

 The ENDEAVOR III Trial is a prospective, multi-center, single-blind, randomized trial that enrolled 436 patients at 29 sites in the US.

 The purpose of this trial is to demonstrate the equivalency of in-segment late lumen loss at 8 months between the Endeavor stent and the Cypher stent for the treatment of single de novo lesions in native coronary arteries 2.

5-3.

5 mm in diameter.

 Patients were randomized to receive the Endeavor stent or the Cypher Sirolimus-Eluting Coronary Stent System.

 Enrollment was completed in September 2004.

.

 The Medtronic Endeavor III Drug Eluting Coronary Stent System Clinical Trial@highlight

To demonstrate the equivalency in in-segment late lumen loss at 8 months between the Endeavor Drug Eluting Coronary Stent System coated with ABT-578 (10 micrograms/mm) and the Cypher Sirolimus-Eluting Coronary Stent System for the treatment of single de novo lesions in native coronary arteries 2.

5-3.

5 mm in diameter.

